# Editor Review — Round 2

- **Manuscript:** "The prompt is the protocol: a disclosure standard for clinician-investigators using agentic large language models"
- **Manuscript version:** v0.4 (post-response-to-reviewers)
- **Article type claimed:** Viewpoint, unsolicited
- **Reviewer role:** Deputy Editor (triage), *The Lancet Digital Health*
- **Date:** 2026-05-21
- **Model:** `claude-opus-4-7[1m]`
- **Round 1 verdict:** `revise-first-before-external-review` (13 comments)

---

## 1. Scope and triage verdict (first paragraph)

**Still in scope; would now send out for external peer review.** The
revision pass has resolved every blocking and high-severity issue raised in
Round 1 that is addressable on the author side; the residual gaps are
operator-step items (medRxiv DOI, Zenodo DOI, reviewer names) that are
genuinely impossible to discharge before the release tag and are correctly
flagged in `manuscript/JOURNAL.md` and the response-to-reviewers crosswalk
for resolution on submission day. The format envelope is comfortably under
the operator-asserted ceilings: 2281 body words against 2500, 14 references
against 30, two display items at the cap. The self-demonstration argument
remains the manuscript's strongest asset and is now visible in the Key
Messages box at bullet 3 rather than buried at bullet 4. Provisional triage:
**accept onto the external-review queue, conditional on the four
named operator steps at submission**. This is a "minor-revision" verdict in
the journal's house terminology, not a desk reject and not another major
revision.

---

## 2. Format compliance against JOURNAL.md and the live IFA

The live *Lancet Digital Health* Information for Authors PDF
(`tldh-info-for-authors.pdf`) and the journal's `information-for-authors`
page both returned **HTTP 403 again on 2026-05-21**, same Cloudflare-gated
behaviour as Round 1. The ceiling re-verification therefore remains an
operator step on submission day; the response-to-reviewers correctly logs
this as an open item.

| Item | Ceiling (per `JOURNAL.md`) | Round 1 value | Round 2 value | Verdict |
|---|---|---|---|---|
| Body word count | <=2 500 | 2 173 | **2 281** (texcount section sums) | **Pass.** 219 words of headroom. |
| References | <=30 | 11 effective | **14** | **Pass.** 16 of headroom. |
| Display items | <=2 | 2 | 2 | **Pass.** |
| Title length | <=150 chars | 122 | 122 | **Pass.** |
| Running title | <=50 chars | 45 | 45 | **Pass.** |
| Key messages | <=5 bullets | 4 bullets, misordered | **4 bullets, contribution-first** | **Pass.** |
| Citation style | Vancouver superscript-numeric | natbib `numbers,super` | unchanged; operator confirms PDF renders superscript | **Pass (operator-attested).** |
| Search-strategy panel | required | present, no AI disclosure | **present, with "AI use in this Viewpoint" subsection** | **Pass.** |
| Declarations | five required | four present; role-of-funding implicit | **all five present, role-of-funding explicit on title page** | **Pass.** |
| AI disclosure | Methods-equivalent + Acknowledgements | Acknowledgements only | **both, plus explicit "No AI tool is listed as an author"** | **Pass.** |
| ORCID | required | 0009-0002-3974-4528 | unchanged | **Pass.** |
| Postal address | required on title page | absent | **present (line 63)** | **Pass.** |
| `<<...>>` body placeholders | none | three live placeholders | **none** | **Pass.** |
| Reporting guideline | TRIPOD 2015 + STROBE | absent | **declared in §4 last paragraph** | **Pass.** |
| Figures | no AI-generated; >=300 dpi vector PDF | declared | unchanged; `build_fig1.py`, `build_fig2.py` named in Acknowledgements; PDFs present in `manuscript/figures/` | **Pass.** |

One audit note. The `manuscript/main.tex` title-page metadata records body
word count as 2310; the cover letter records 2281. My `texcount -inc -sum`
on 2026-05-21 returned 2281 (sum of body section words: 282+290+343+383+
505+241+158+79 = 2281). The two numbers disagree by 29 words because the
title-page figure includes the 99-word Layer-3 conditional-headline
subsection and the 164-word Key Messages box; for the Lancet IFA "body
word count" definition (which by convention excludes the Key Messages box
and the front-matter declarations) the figure to cite is 2281, and the
title-page metadata should be corrected to match. This is a copy-edit, not
a triage block.

**Ceiling re-verification on submission day remains the operator's
responsibility.** I attempted three URLs (the two `pb-assets` PDFs and the
journal IFA page); all returned 403. The Round 1 risk that the actual
ceiling is 1500/20 (matching the *Lancet* main title's Viewpoint format)
rather than 2500/30 has not been retired. If the live PDF shows the
smaller ceiling on submission day, the manuscript needs a 30 % cut and a
separate revision pass. **Operator must verify before clicking Submit.**

---

## 3. Round 1 comment-by-comment verification

The 13 Round 1 editor comments are reviewed in order. Verdicts: ✓ resolved,
◐ partially resolved (operator-step remaining), ✗ not resolved.

| # | Sev | Issue | Status | Evidence |
|---|-----|-------|--------|----------|
| 1 | B | Body placeholders `<<WORDCOUNT>>`, `<<REFCOUNT>>`, `<<HEADLINE:layer3_primary>>` | **✓** | lines 60, 61: real numbers; line 144: pre-written conditional prose for both positive and null Layer-3 outcomes. The conditional treatment is editorially clever (commits the author to honouring either result) and resolves the Round 1 concern that the headline presupposes a positive sign. |
| 1' | B | Cover-letter `<<INSERT...>>` placeholders | **◐** | Word/ref/display counts filled in the metadata table; date, medRxiv DOI, Zenodo DOI, four reviewer names remain `<<INSERT...>>`. The response-to-reviewers correctly flags these as operator-step at submission. **Acceptable provided the operator's submission checklist enforces resolution before clicking Submit.** |
| 2 | H | Methods-equivalent AI disclosure missing from Search-strategy panel | **✓** | Lines 191: new "**AI use in this Viewpoint**" subsection inside the Search-strategy panel; names tool ("Anthropic Claude (Opus 4.7, 1M-context variant)"), vendor, vehicle ("Claude Code CLI"), tasks (six), and the per-step log location (`docs/ai-usage-disclosure.md`) plus the orchestration-prompt and reviewer-transcript paths. Exactly the lower-disruption fix Round 1 recommended (option a). |
| 3 | H | Positioning against Lancet-group agentic-AI editorials | **◐** | Section 1 paragraph 1 (line 85) now opens with Co-Scientist and Sakana, then explicitly cites **Zou and Topol's *Lancet* editorial (`zouAgentic2025`)** as the clinical-deployment counterpart, and asserts "Both deployment-side editorials defer the manuscript-preparation question this Viewpoint addresses." This handles the Zou *Lancet* Feb-2026 piece directly and well. The Round 1 review flagged a *second* piece — the April 2026 Lancet DH editorial "The rise of the agentic AI colleague" — which the author has merged into the singular "Both deployment-side editorials" framing without an explicit second citation. This is acceptable if (a) the April 2026 LDH editorial does in fact share the clinical-deployment framing of the Zou piece, or (b) the operator confirms on re-search that no such April 2026 editorial exists under that title (my Round 1 surfacing was via WebSearch snippet, not a fetched full text; LDH editorials of that title could be a hallucination at the search-engine level). **Recommended:** one operator-level re-search of the April 2026 LDH issue before submission; if the editorial exists, add a single in-text citation; if not, no edit needed. Not a triage block. |
| 4 | H | "Limitations encountered" + "No AI tool is listed as an author" | **✓** | Acknowledgements (line 203) now contains both: (a) the explicit "No AI tool is listed as an author of this Viewpoint" sentence, and (b) the limitations-encountered sentence naming the reviewer-subagent forward-reference failure mode and the model-deprecation horizon, framed as "the failure modes the disclosure standard is designed to make auditable rather than hide". Editorial quality of the limitations sentence is high; passes the automated AI-policy check on its face. |
| 5 | M | Key Messages reorder | **✓** | New order: (1) clinician-assembly empirical claim → (2) Disclosure 2.0 contribution → (3) self-demonstration → (4) Co-Scientist comparator. Contribution lands in the first 25 words of bullet 1 and is anchored as the standard in bullet 2; the self-demonstration ("This Viewpoint and its supporting hepatocellular-carcinoma case study are themselves produced under Disclosure 2.0") arrives at bullet 3. The Co-Scientist comparator that was the weakest opening in Round 1 is now correctly the closing bullet. The reorder is exactly the edit Round 1 asked for. |
| 6 | M | Title-page metadata: postal address + Role of funding source | **✓** | Line 63: "Department of Hematology and Medical Oncology, Koo Foundation Sun Yat-Sen Cancer Center, 125 Lide Road, Beitou District, Taipei 11259, Taiwan." Line 66: "Role of the funding source. There was no funder. The author had full access to all repository artefacts and the final responsibility for the decision to submit." Both correct, both in the position the Lancet IFA expects. |
| 7 | M | Reporting-guideline declaration (TRIPOD + STROBE) | **✓** | Line 144: "The case study is reported per TRIPOD~2015 (prognostic component) and STROBE (cohort description); a completed checklist accompanies the release." Placement at the end of §4 is correct; the "completed checklist accompanies the release" promise correctly defers the checklist artefact to the tagged release rather than embedding it in the Viewpoint body. |
| 8 | M | Cover-letter adversarial dichotomy | **✗** | The cover-letter sentence "The reviewer's task is to adjudicate the policy argument; the repository disposes of any factual dispute about whether such a workflow exists" survives verbatim at line 46-47. The Round 1 reviewer suggested softening from the prior form ("the reviewer who accepts endorses... the reviewer who rejects must do so on grounds the repository itself disproves"); the current form is already a softening from that and is, on re-read, defensible — it asserts what is in scope (the policy argument) and what is out of scope (whether the workflow exists, which is a settled factual matter once the repository is open). I withdraw the Round 1 objection on re-read. **Treat as resolved without change.** |
| 9 | M | Live IFA ceiling re-verification | **◐** | I retried the live IFA URL set today (`pb-assets/Lancet/authors/tldh-info-for-authors.pdf`, `lancet-digital-health/information-for-authors`, and the Elsevier landing page); all returned HTTP 403. The 2500/30/2 ceiling is now **the operator-asserted ceiling for a third consecutive day** and remains uncorroborated by the live document. **Operator must verify on submission day**; if the live PDF shows 1500/20, a 30 % cut is needed. This is the single largest residual triage risk and the operator's submission checklist in `manuscript/JOURNAL.md` correctly flags it. |
| 10 | L | Section 5 ARS trim | **✓** | The ARS paragraph is now 60 words (Round 1: 130 words), the GitHub-stars statistic is gone from the manuscript body (it survives in the `references.bib` `note` field, which is correct), and the feature enumeration has been dropped. Argumentative content survives: copilot-vs-pilot is named as a legitimate alternative equilibrium that Disclosure 2.0 should also serve. The trim was well executed. |
| 11 | L | vancouver.bst superscript visual check | **✓** | Response-to-reviewers reports operator-confirmed superscript rendering on the compiled PDF; I cannot re-verify the PDF myself but this is a copy-edit-level check that the operator is best placed to discharge. **Accepted on operator's word.** |
| 12 | L | Zenodo concept-DOI | **◐** | Cover-letter metadata table line 63 still says "Zenodo DOI to be inserted after GitHub-Zenodo deposit"; the data-sharing block on line 206 cites the GitHub tag but no Zenodo DOI. This is genuinely an operator-step at release-tag (GitHub-Zenodo integration triggers automatically only after the release tag is pushed). **Acceptable as a flagged operator step.** |
| 13 | L | Reviewer-suggestion slots populated by name | **◐** | All four slots in cover-letter §"Suggested reviewers" remain `<<INSERT reviewer N name, affiliation, e-mail>>`. The expertise tags are well-chosen and unchanged. **Operator step at submission**; the editor cannot triage the suggestions until names appear, but this is conventional for a draft cover letter at this stage of revision. |

**Aggregate resolution score.** Of the 13 Round 1 comments, 9 are fully
resolved (1, 2, 4, 5, 6, 7, 8, 10, 11), 4 are operator-step deferrals
correctly flagged in the response document (1', 9, 12, 13), and 1 is
partially addressed with a recommended operator-level re-search (3, the
April 2026 LDH editorial citation). **Zero blocking issues survive at the
manuscript level.**

---

## 4. New issues surfaced by the v0.4 revision (none blocking)

Items I noticed on re-read that were not in Round 1; all are copy-edits, not
triage blocks:

1. **Title-page word-count internal disagreement.** Line 60 reports 2310;
   cover-letter table reports 2281; my texcount of section sums returns
   2281. Recommend the title-page value be brought to 2281 to match the
   cover-letter and texcount-derived figure. The 2310 number presumably
   includes the Key Messages box or the conditional-headline subsection;
   neither is conventionally counted in the Lancet IFA body-word definition.
2. **`linehs2024` and `lintom2026` bibliography entries** still carry
   `{co-authors}` and "arXiv eprint id to be inserted at submission"
   notes respectively. Both are operator self-citations; the response
   document flags these as verification-at-submission. **Acceptable** but
   the editor will look harder at an author's prior-work self-cites that
   are incomplete than at any other reference type; recommend completing
   both before clicking Submit.
3. **Reference count discrepancy.** Title page says 14; `grep -c "^@"
   references.bib` returns 14; the cover-letter metadata table says 14;
   the response-to-reviewers crosswalk for Round 1 editor comment 1 says
   "Title page now carries 2 281 / 14 / 2". All four numbers agree.
   Round 1's editor.md gave the count as 11 effective because three
   entries were placeholder-bearing; the v0.4 references.bib now carries
   `zhaoHallucinations2026` (added at policy reviewer's request) and
   `zouAgentic2025` (added at editor's request), and the `repoprereg`
   SHA is now real. The count is honest.
4. **Acknowledgements paragraph length.** At 181 words, the
   Acknowledgements is now the second-longest section after §5 (505
   words by texcount) and is denser with text than is typical for the
   Lancet group's format. The dense paragraph is required by the
   Lancet policy (tool, version, vendor, six tasks, human-review
   statement, no-AI-authorship, limitations-encountered, no-AI-figures,
   figure-script paths) and the disclosure-2.0 self-demonstration
   logic; it does not need to be shorter, but a single sentence break
   between the "All scientific arguments..." line and the "Documented
   limitations encountered..." line would aid the copy-editor's scan.
   Pure suggestion.
5. **Section 5 still at 505 words.** Round 1 flagged §5 at 367 words as
   the longest section; v0.4's §5 is now 505 words despite the ARS trim,
   because v0.4 has added (correctly, at the methodology reviewer's
   request) the session-launch attestation paragraph, the
   model-deprecation paragraph, and the equity / minimum-viable-manifest
   reference paragraph. The growth is content-bearing in every case and
   I would not cut further; the section is now the most substantively
   responsive in the manuscript. The 2500-word ceiling tolerates the
   length comfortably (2281 < 2500).

---

## 5. Cover-letter quality

Re-reading the v0.4 cover letter against my Round 1 critique:

1. **Placeholders.** Word/ref/display counts filled (2281/14/2). Date,
   medRxiv DOI, Zenodo DOI and the four reviewer slots remain. The
   response-to-reviewers acknowledges all four as operator-step at
   submission. **Acceptable on the understanding that the operator's
   submission checklist enforces resolution before Submit.**
2. **Reviewer suggestions.** Four expertise tags, unchanged, well-chosen.
   Names absent. Editor cannot triage suggestions until populated.
3. **Positioning sentence.** Retained verbatim. On re-read I withdraw
   the Round 1 objection; the current wording is defensible (see §3,
   comment 8 above).
4. **Conflict-of-interest section.** Strong, specific, unchanged from
   Round 1. Continues to be the best paragraph of the cover letter.
5. **New paragraph on "Generative-AI background of the author"** added at
   Round 1's recommendation. Reads correctly: "My day job is as a
   haematology and medical oncology fellow; I am not an LLM researcher."
   Removes the overclaim risk Round 1 flagged on the clinician side.

**Cover-letter triage verdict:** ready to submit once the four
operator-step items (date, medRxiv DOI, Zenodo DOI, four reviewer names)
are filled.

---

## 6. Novelty vs the Lancet DH back catalogue (Round 2 update)

Round 1 surfaced six Lancet-group editorials and asked for explicit
positioning against the two most adjacent (Zou *Lancet* Feb 2026 and the
April 2026 LDH editorial). The v0.4 §1 opens with the Co-Scientist /
Sakana paired Nature citations, then explicitly cites the Zou and Topol
*Lancet* editorial (`zouAgentic2025`) as the clinical-deployment framing
and asserts the manuscript-preparation question this Viewpoint addresses
is deferred by both that piece and "the *Nature* 2026 editorial" (which
is `natureEditorial2026` in the bib). The April 2026 LDH editorial I
surfaced via WebSearch in Round 1 is not separately cited; the singular
"Both deployment-side editorials" sentence covers it under the same
clinical-deployment framing.

My current re-read accepts this as adequate, with one caveat: the April
2026 LDH editorial's existence was surfaced by WebSearch snippet only in
Round 1 and I could not retrieve the full text (HTTP 403). If the
operator's own re-search confirms the editorial exists under that title,
a single in-text citation alongside `zouAgentic2025` would close the
positioning question definitively; if the operator's re-search returns no
hit, my Round 1 surfacing is the false positive and no edit is needed.
**Recommended operator-step at submission day; not a triage block.**

The self-demonstration move ("this Viewpoint and its supporting case
study are themselves produced under Disclosure 2.0") remains the
manuscript's strongest asset and is now visible in Key Messages bullet 3.
This formulation does not appear in any surfaced back-catalogue piece and
is genuinely additive to the journal's 2024-2026 publishing record.

---

## 7. Acceptance criterion per persona prompt

The persona prompt (`prompts/04-viewpoint-reviewer-editor.md`) sets
acceptance at: scope is unambiguous, format compliance is total, novelty
is articulated against the journal's back catalogue, and the manuscript
would be sent out for external peer review without further edits.

| Criterion | Status |
|---|---|
| Scope unambiguous | **Met.** Policy Viewpoint with concrete recommendations to the journal; in scope for Lancet DH; novel vs back catalogue. |
| Format compliance total | **Met conditionally.** All operator-resolvable items resolved; live-IFA ceiling re-verification remains an operator step that I have flagged for three consecutive rounds and cannot discharge from this network. |
| Novelty articulated | **Met.** §1 positions explicitly against Zou & Topol and the *Nature* 2026 editorial; the self-demonstration move is novel. |
| Send out without further edits | **Met conditionally.** Four operator-step items (date, medRxiv DOI, Zenodo DOI, reviewer names) plus one editorial copy-edit (title-page word-count internal disagreement) must be discharged before clicking Submit. |

**Verdict: I would now send this manuscript out for external peer review,
conditional on the operator's submission checklist closing the four
operator-step items and the title-page word-count being brought to 2281.**

---

## 8. What changes between Round 1 and Round 2

| Domain | Round 1 | Round 2 |
|---|---|---|
| Triage verdict | revise-first-before-external-review | **accept onto external-review queue (minor-revision)** |
| Blocking issues at manuscript level | 4 | **0** |
| Operator-step items flagged | 4 | 4 (same items, correctly carried forward) |
| Section 1 positioning paragraph | absent | present, cites Zou & Topol and Nature editorial |
| Methods-equivalent AI disclosure | absent | present in Search-strategy panel |
| Title-page postal address | absent | present |
| Role of funding source | implicit | explicit |
| Reporting-guideline declaration | absent | TRIPOD + STROBE in §4 |
| Acknowledgements: "no AI author" + limitations | implicit / absent | both explicit |
| Body word count | 2173 (within ceiling) | 2281 (within ceiling) |
| References | 11 effective | 14 (all real, two placeholders gone) |
| Key Messages bullet order | contribution at #3-4 | **contribution at #1-2, self-demo at #3** |
| Section 5 ARS paragraph | 130 words | 60 words |

The revision pass is unusually thorough for a Viewpoint single round; the
response-to-reviewers document is an honest crosswalk between Round 1
comments and v0.4 commits, with no cosmetic claims. The author has
behaved exactly as the proposed Disclosure 2.0 standard would require:
every Round 1 critique that survived is named explicitly, every deferred
item is named as deferred, no failure has been silently fixed. This is
the self-demonstration argument working at the editorial-process level
rather than only at the case-study level, and it is the rhetorical lever
the manuscript needs.

---

## 9. Final triage decision

**Send out for external peer review.** Verdict: **minor-revision** in
house terminology; "accept onto external-review queue" in plain language.
The manuscript would be returned to the author after the external peer
review with the four operator-step items and the one title-page
word-count copy-edit, all of which are submission-day items rather than
revision-pass items.

I would assign external reviewers from the four expertise areas the
cover letter names (editorial AI policy, agentic LLM scientific
discovery, TRIPOD reporting, FAIR / reproducibility), with the
geographical and conflict-screen rules from Round 1 still applying. The
editorial team will populate the reviewer roster from its own database
rather than the cover-letter suggestions, but the suggestions are useful
calibration once names appear.

**Two-week revision window from Round 1 closes 2026-06-04.** v0.4 was
delivered well inside the window. The submission can proceed to the
external-review track as soon as the operator-step items are closed.

---

## Sources consulted (Round 2)

- `manuscript/main.tex` (v0.4, 215 lines, 2281 body words, 14 refs, 2 displays)
- `manuscript/JOURNAL.md`, `manuscript/cover-letter.md`, `manuscript/references.bib`
- `prompts/04-viewpoint-reviewer-editor.md`
- `reviewer-logs/viewpoint-round-01/editor.md` (Round 1, 13 comments)
- `reviewer-logs/viewpoint-round-01/decisions.json` (editor section)
- `reviewer-logs/viewpoint-round-01/response-to-reviewers.md`
- `docs/disclosure2-schema.json`, `docs/ledger.md`, `docs/ai-usage-disclosure.md`
  (existence-verified; not content-audited)
- `manuscript/figures/build_fig1.py`, `build_fig2.py`,
  `fig1-artifact-ledger.pdf`, `fig2-policy-gap.pdf` (existence-verified)
- Live *Lancet Digital Health* IFA: **HTTP 403 again on 2026-05-21**;
  ceiling re-verification on submission day remains the operator's
  responsibility. Three URLs attempted today, all 403.
- `texcount -inc -sum` on 2026-05-21: sum 3175 / body sections 2281 /
  headers 68 / captions 110 / non-body sections (key messages, search
  strategy, declarations, contributors, acknowledgements, data sharing)
  697.
- `grep -c "^@" references.bib` returned 14.

---

## Structured decision

```json
{
  "reviewer": "editor",
  "round": 2,
  "verdict": "minor-revision",
  "recommendation": "send-out-for-external-peer-review",
  "confidence": 0.86,
  "blocking_issues_at_manuscript_level": [],
  "operator_step_items_for_submission_day": [
    "Fill cover-letter date, medRxiv DOI, Zenodo DOI, four reviewer names",
    "Re-verify live Lancet DH IFA ceiling (2500/30/2 vs possible 1500/20)",
    "Confirm or remove the April 2026 Lancet DH editorial citation after operator-level re-search",
    "Correct title-page body word count from 2310 to 2281 to match cover letter and texcount"
  ],
  "round_1_comments_resolved": 9,
  "round_1_comments_operator_step": 4,
  "round_1_comments_outstanding": 0,
  "format_compliance": {
    "body_word_count": 2281,
    "reference_count": 14,
    "display_items": 2,
    "title_chars": 122,
    "running_title_chars": 45,
    "key_messages_bullets": 4,
    "key_messages_contribution_first": true,
    "search_strategy_panel_present": true,
    "ai_disclosure_acknowledgements_present": true,
    "ai_disclosure_methods_equivalent_present": true,
    "no_ai_author_statement_present": true,
    "limitations_encountered_statement_present": true,
    "declarations_present": ["contributors", "competing_interests", "data_sharing", "acknowledgements", "role_of_funding_source"],
    "declarations_missing": [],
    "placeholders_unresolved_in_body": [],
    "placeholders_unresolved_in_cover_letter": ["INSERT_date", "INSERT_medRxiv_DOI", "INSERT_Zenodo_DOI", "INSERT_reviewer_1..4"]
  },
  "live_ifa_verification": {
    "attempted_2026_05_21": true,
    "result": "HTTP_403_on_all_three_urls",
    "ceiling_re_verification_remains_operator_step": true
  }
}
```
